MCRB Seres Therapeutics, Inc.
Price Chart
Executive Summary
Seres Therapeutics presented preclinical data for SER-603, a next-generation live biotherapeutic for IBD, at DDW 2026. The data is early-stage (in vitro) and does not provide financial or regulatory catalysts, limiting near-term stock impact.
Actionable Insight
Monitor for IND filing or partnership announcements. Given early-stage data, low probability of near-term stock movement; any upside would require positive clinical data or a collaboration deal.
Key Facts
- SER-603 is a preclinical cultivated live biotherapeutic candidate for inflammatory bowel disease (IBD).
- Data presented at DDW 2026 was selected for 'Poster of Distinction' recognition.
- SER-603 is designed to modulate the GI microbiome, induce mucosal healing, and reduce inflammatory stimuli without immunosuppression.
- The company is advancing SER-603 through IND-enabling activities and seeking development partners.
Financial Impact
No financial data disclosed. No revenue or earnings impact at this preclinical stage.
Risk Factors
- Preclinical results may not translate to clinical efficacy.
- Company faces going concern risk and needs additional funding.
- SER-603 is early stage; clinical development timeline is years away.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286554 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
4d ago
|
8-K
| $7.80 awaiting T+5 | awaiting T+5 | — | $6.28 (−19.49%) |
|
Jun 5, 2026
4d ago
|
Press Release
| $6.99 awaiting T+5 | awaiting T+5 | — | $6.28 (−10.16%) |
|
May 19, 2026
21d ago
|
Insider Cluster
| $7.66 $7.63 | ▼ −0.39% | ▼ −1.63% | $6.28 (−18.02%) |
|
May 5, 2026
5w ago
|
8-K
| $7.50 $7.96 | ▼ −6.13% | ▼ −4.15% | $6.28 (+16.27%) |
|
May 5, 2026
5w ago
|
Press Release
| $7.50 $7.84 | ▼ −4.53% | ▼ −2.55% | $6.28 (+16.27%) |
|
May 4, 2026
5w ago
|
Press Release
| $7.69 $7.84 | ▲ +1.95% | ▼ −0.99% | $6.28 (−18.34%) |
|
Mar 12, 2026
12w ago
|
8-K
| $9.05 $9.08 | ▲ +0.33% | ▲ +1.31% | $6.28 (−30.61%) |
|
Mar 12, 2026
12w ago
|
Press Release
| $9.05 $9.08 | ▲ +0.33% | ▲ +1.31% | $6.28 (−30.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access